Optical coherence tomography using tissue clearing for skin disease diagnosis

Author(s):  
Galina Petrova ◽  
Elena Derpalyuk ◽  
Natalia Gladkova ◽  
Felix Feldchtein ◽  
Nikolay Nikulin ◽  
...  
2003 ◽  
Author(s):  
Galina A. Petrova ◽  
Elena Derpalyuk ◽  
Natalia D. Gladkova ◽  
Felix I. Feldchtein ◽  
Nikolay Nikulin ◽  
...  

Rheumatology ◽  
2020 ◽  
Vol 59 (Supplement_2) ◽  
Author(s):  
Duygu Temiz Karadag ◽  
Giovanni Lettieri ◽  
Valentina Picerno ◽  
Ozcan Gundogdu ◽  
Maria Carmela Padula ◽  
...  

Abstract Background The modified Rodnan skin score (mRSS) is the current gold standard for skin assessment in systemic sclerosis (SSc) both in clinical trials and practice. Several studies have reported that skin high frequency ultrasound (HFUS) and, more recently, optical coherence tomography (OCT) are able to reflect the severity of the skin disease in SSc. Aim of the study was to compare OCT and HFUS in the assessment of skin involvement in SSc. Methods Dorsal forearm skin of consecutive diffuse cutaneous SSc (dcSSc) patients and matched-healthy controls (HC) were scanned using OCT and HFUS by investigators blinded to the clinical details using Vivosight scanner (1 assessor) and Esaote MyLab70 equipped with a 22 MHZ probe (2 assessors) respectively. Minimum Optical Density (MinOD), Maximum OD (MaxOD) and OD at 300 micron-depth (OD300) (OCT) and skin thickness (HFUS) were measured. Clinical involvement was assessed by a blinded operator using the mRSS and results were cross matched with imaging data. Statistical analysis was performed using GraphPad Prism software V.7.0. Results A total of 88 OCT images and 176 HFUS images were obtained from 22 dcSSc patients [20 Female, mean age 49 (±11) years, 12 with < 5 years disease duration) and 22 HC (20 Female, mean age 50.7 (±6.7) years]. All OCT measures (MinOD, MaxOD and OD300) were significantly lower in SSc patients than in HC (p = 0.011, p < 0.0001, p < 0.0001 respectively). HFUS showed a lower performance in discriminating SSc skin vs HC compared to OCT (overall AUC 0.6 vs 0.72, 0.8 and 0.89 for MinOD, MaxOD and OD300 respectively). Nevertheless, mean HFUS skin thickness significantly correlated with mRSS at site of analysis (r = 0.47, p = 0.0013) and showed overall excellent interobserver reliability between assessors (ICC >0.8). Importantly, MaxOD and OD300 negatively correlated with HFUS skin thickness (r=-0.32, p = 0.035; r=-0.31, p = 0.039). Conclusion OCT of the skin has been previously validated against skin biopsy in SSc. Our results validate HFUS against OCT and indicate that HFUS of the skin is a reliable measure of skin involvement. Further, here we show that HFUS and OCT outperform each other in measuring different aspects of skin involvement in SSc and they offer complementary surrogate outcome measures of disease. Disclosures D. Temiz Karadag None. G. Lettieri None. V. Picerno None. O. Gundogdu None. M. Padula None. G.A. Mennillo None. A.A. Padula None. F. Del Galdo None. S. D'Angelo None. G. Abignano None.


2015 ◽  
Vol 09 (02) ◽  
pp. 147 ◽  
Author(s):  
Giovanni Staurenghi ◽  
◽  
◽  
◽  
Jose Cunha Vaz ◽  
...  

AngioPlex™ optical coherence tomography (OCT) is a new approach to diagnostic imaging in retinal disease. This technology uses amplitude and phase aspects of the OCT signal and novel algorithms to enable highly detailed visualisation of the retinal microvasculature. This system detects capillary flow rather than the presence of an injected dye. Unlike fluorescein angiography (FA), AngioPlex OCT imaging can discriminate capillaries at the superficial and deep retina and can also generate a colour map of the retinal vessels providing unparalleled views of diseased capillaries and net structures. Retinal and choroidal pathologies that are amenable to AngioPlex OCT examination include diabetic retinopathy (DR), vein occlusions, age-related macular degeneration and pathological myopia. In addition, AngioPlex OCT can be used to explore the vasculature of the optic nerve. These applications have considerable potential for improved retinal and choroidal disease diagnosis, but further experience and debate are needed to fully interpret the images. AngioPlex OCT is rapid, non-invasive and improves the patient experience and has been granted US Food and Drug Administration (FDA) 510(k) clearance for clinical use. The convenience and the range of retinal disease applications may encourage widespread adoption of the technology. AngioPlex OCT may therefore become a standard initial examination step for patients with retinal disease prior to and during treatment and may also indicate where further investigations including FA or indocyanine green are necessary.


Sign in / Sign up

Export Citation Format

Share Document